Debio 4126 controlled release - Debiopharm
Alternative Names: Debio-4126Latest Information Update: 08 Jan 2025
Price :
$50 *
At a glance
- Originator Unknown
- Developer Debiopharm
- Class Antineoplastics; Somatostatins
- Mechanism of Action Growth hormone-releasing hormone inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Acromegaly; Neuroendocrine tumours
- Preclinical Cancer
Most Recent Events
- 03 Dec 2024 Debiopharm terminates phase I trial in Neuroendocrine tumours and Acromegaly (Combination therapy) in Sweden, Spain, Russia, Portugal, Poland, Italy, Israel, Hungary, Germany, France, United Kingdom, Denmark (IM), due to strategic reasons (NCT05364944)
- 18 May 2022 Phase-I clinical trials in Acromegaly (Combination therapy) in Sweden, Spain, Russia, Portugal, Poland, Italy, Hungary, Israel, Germany, United Kingdom, France, Denmark (IM) (NCT05364944)
- 18 May 2022 Phase-I clinical trials in Neuroendocrine tumours (Combination therapy) in Sweden, Spain, Russia, Portugal, Poland, Italy, Israel, Hungary, Germany, France, United Kingdom, Denmark (IM) (NCT05364944)